Abstract:W-01-A Optimizing diagnosis in Canadian cancer care: Findings, recommendations, next steps, and implications for key stakeholders including oncology nurses 137 W-01-B Integration of oncofertility screening, assessment and supports for adolescent and young adult (AYA) cancer patients: A workshop for oncology nurses 137 W-01-C Optimizing care – Introducing a toolkit to inform nursing assessment and intervention for age-related changes in older adults with cancer 138 W-02-A Health equity and equity-oriented cancer care: What it is, and why it matters to oncology nursing 138 W-02-B Leading the way: Increasing nurses’ contributions to genomics and precision healthcare 138 W-03-A Hematology nursing workshop 139 W-03-B Oncologic emergencies workshop 139 W-04-A Excellence in oncology nursing leadership – Nursing leadership in times of crisis 139 W-05-A I’d tap that: Am I here in vein? 140 W-05-B Canadian Indigenous cancer strategy across the spectrum 140 W-06-A International partnerships in cancer care – Cultural bridging for oncology nurses 140 W-06-B Reflecting and connecting: Optimizing sexual health and intimacy after a cancer diagnosis 140 W-06-C Writing for peer-reviewed journals: Getting started 141 I-1-A Connection, reflection and celebration: Coming together to develop a sexual and gender diversity in cancer care (SGDc) program 141 I-1-B Examining the unmet needs of Panjabi-Sikh patients during the treatment phase of cancer care 141 I-1-C A time for reflection: Exploring the unique perceptions and experiences of Black patients with mental health issues at end of life 142 I-1-D Digital information needs and ehealth literacy of older adults with cancer 142 I-2-A Understanding factors influencing Canadian oncology nurses’ discussing cannabis use with patients experiencing chemotherapy-induced nausea 142 I-2-B Utilizing patient reported outcomes (PROs) and toxicity assessment to improve efficiencies in nursing practice: A stepped assessment approach 143 I-2-C Chewing the fat: A nurse’s guide to understanding the role of adipose tissue in cancer cachexia 143 I-2-D Streamlining care: A nurse-led inter-hospital febrile neutropenia project 143 I-3 Enhancing competency-based learning in systemic therapy administration using a standardized and blended online and workshop model 144 I-4-A Designing a proof-of concept of an app to coordinate nurse-provided respite care services for families coping with palliative-stage cancer 144 I-4-B Implementing virtual care overnight: A pilot project evaluating the available technologies for virtual patient care 144 I-4-C Connecting the “bots”: Leveraging digital technology to better serve our patients and their families 145 I-4-D Transitioning breast cancer surgery education online: A COVID-19 quality improvement project 145 I-5-A Critical shortages of chemotherapy-certified nurses and practice challenges: Management of HDMTX toxicities 145 I-5-B Common symptom clusters in advanced cancers 146 Abstract number Oral Presentation titles Page number I-5-C Early intervention of harm reduction for hematology patients with substance use disorder 146 I-5-D Surgical insertion of tunneled drainage catheters: Implications for care in palliative patients 146 I-6-A Care coordination: Optimizing the scope and role of oncology nurses to meet the individual needs of patients and families within cancer care 146 I-6-B Connecting resources and fostering partnerships to build capacity in the outpatient systemic therapy setting 147 I-6-C Enhancing practice for oncology nurses – Systemic therapy initial and continuing competency education 147 I-6-D The pan-Canadian Oncology Symptom Triage and Remote Support (COSTaRS) online tutorial: Retrospective pre-/post-test study 147 II-1-A Medical Assistance in Dying for mature minors 148 II-1-B Psychosocial effects of the COVID-19 pandemic on pediatric cancer survivors followed in adulthood: Lessons learned and future implications 148 II-2-A Nursing leadership in the pre-diagnostic phase of care of suspected patients with lung cancer (bilingual session) 148 II-2-B Une théorisation ancrée sur l’évolution des perceptions du rôle des infirmières lors du soin de l’aide médicale à mourir 149 W-II-3 Cancer and social justice: What’s advocacy got to do with it? 149 II-4-A Educating patients on immune checkpoint inhibitors: Ensuring a patient centred learning approach 149 II-4-B Unveil the experiential knowledge acquired by healthcare professionals to accompany people touched by cancer: Educational perspectives 150 II-4-C ELSKA – A simple patient reported outcome and teaching tool developed by an old bedside nurse 150 II-5-A Urgent CancerCare Clinic - An introduction 150 II-5-B A smart move: The development and implementation of a nurse-led, non-hazardous infusion clinic 151 II-5-C An integrative review of cardio-oncology interdisciplinary clinics and the role for nursing 151 II-6-A Early integration of palliative care 151 II-6-B Automatic referrals to palliative care for newly diagnosed stage IV lung cancer patients: Connecting research and clinical practice 152 III-1-A Reflection: Making the connection between advanced testicular cancer and the COVID-19 pandemic 152 III-1-B Early new patient assessment at BC Cancer – Victoria: A patient and staff experience survey 153 III-1-C Can you hear me? The shift to virtual patient education classes during a global pandemic 153 III-1-D Provincial oncology nursing telepractice standards development and evaluation during the pandemic response 153 III-2-A Preparing for life after primary gynecological cancer treatment: An educational resource for survivors and caregivers 153 III-2-B Behind cancer survivorship: Three extensive experiential learning pathways 154 III-2-C Exploring post-treatment concerns for survivors of five common cancers: Alberta results from the pan-Canadian Transitions Study 154 W-III-3 Finding hope in difficult times: Advancing nursing leadership in climate action 155 III-4-A An integrative review on the oncology nurse navigator role in the Canadian context 155 III-4-B Driving a hybrid: Navigating the road to success in creation of a new brachytherapy perioperative course for registered nurses 155 III-4-C Supporting the novice nurse in an outpatient oncology setting: One centre’s approach to navigating the new oncology nurses’ journey from novice to expert 155 Abstract number Oral Presentation titles Page number III-4-D Starting from scratch, growing our own 156 III-5-A Nurse-led telehealth interventions for symptom management in patients with cancer: A systematic review 156 III-5-B Telephone completion of patient self-reporting history by registered nurses: A survey to evaluate its effectiveness and strategies for improvement 157 III-5-C The art of variation: Distress screening implementation in Rossy Cancer Network Hospitals 157 III-5-D Examining a nurse practitioner-led intervention to provide supportive care for gynecological cancer survivors entering surveillance 157 III-6-A Dropping off the treatment wagon: Barriers to cancer treatment and care for people experiencing health and social inequities 158 III-6-B Health and healthcare equity in the Canadian cancer care sector: A rapid scoping review 158 III-6-C Choosing MAID: Learning from bereaved family members of cancer patients who chose MAID 159 III-6-D Patient-targeted resources to support decisions about Medical Assistance in Dying in Canada: An environmental scan 159 AWA2 Moving away from “watch and wait” to more proactive language – An NPs approach to reducing distress in CLL practice 159 IV-1-A Goals of care discussion: The 7th vital sign for oncology 159 IV-1-B Oncology nurses’ perceptions of advanced care planning: A narrative review 160 IV-1-C Evaluation of an electronic patient-provider communication tool to facilitate goals of care discussions 160 IV-2-A The evolution of effective collaborative management of PARPi therapy in ovarian cancer 161 IV-2-B A primary care nurse (PCN) role in the preparation of patients planned for autologous stem cell transplant (ASCT) 161 IV-2-C Developing a nurse practitioner-led ambulatory clinic for patients with gynecological malignancies 161 W-IV-3 Together again – Empowering new oncology nurses through education and mentorship 161 IV-4-A What have I done for me lately?: Compassion fatigue and resilience of oncology team members and the creation of a self-care space, “The Well” 162 IV-4-B From wellness baskets to remote anti-cancer drug administration: Empowered nurses drive key COVID successes 162 IV-4-C Help we are in crisis – On the path to a stronger, more connected team 162 IV-5-A The role of the patient representative in the cancer patient journey 163 IV-5-B MyChart patient portal: A patient empowerment tool 163 IV-5-C Connecting and reflecting: The nurse practitioner role in supporting research to assess unmet needs of men diagnosed with testicular cancer 163 IV-6-A Supportive care needs of young women with gynecological cancer 164 IV-6-B Understanding the use of telephone triage by cancer patients in Alberta: Exploring the data 164 IV-6-C Age analysis of patient-reported outcome measures: Understanding the symptom experience and concerns of older Albertans with cancer 164 V-I-A The experiences of family caregivers caring for their relatives diagnosed with advanced cancer in Ghana 165 V-I-B A scoping review of characteristics and outcomes of nurse-led palliative care models in low- and middle-income countries 165 V-2-A Les soins virtuels en cancérologie : le point de vue du patient 165 V-2-B Implantation de l’application Belong en oncologie pour les patients et leurs familles dans leur routine de soins 166 V-2-C Création d’une programme d’orientation en cancérologie (POC) panquébécois 166 Abstract number Oral Presentation titles Page number W-V-3 Questions you had about doing cancer care nursing research but were too afraid to ask 166 V-4-A Application of a dynamical neurofeedback brain training intervention to address post-cancer cognitive impairment: Results of a pilot study 167 V-4-B Connecting with people when they are living with cancer and cognitive disorders 167 V-5-A Designing and delivering a distance learning oncology nursing graduate certificate program: A step on the path to becoming an oncology APN 167 V-5-B Building health human resource capacity to support complex malignant hematology care 168 V-5-C Educating primary care providers about sexual health disturbance in breast cancer survivorship care using virtual simulation: A feasibility study 168 V-6-A Connection, reflection, celebration: The personal impact of the celebratory bell in cancer care 168 V-6-B A long road home: Challenges for Inuit patients wanting to return to the North for end of life 169 V-6-C Historical perspectives: Gynecological oncology nursing and high-dose brachytherapy over the years 169 AWA3 Collaborating across settings to shape the future of oncology nursing after-hours toxicity management support 170 Poster Presentations A-1 Nursing-led benchmarking project: Exploring nurses’ role across diagnostic breast centres 171 A-2 Venipuncture in the affected limb of patients with breast cancer: Translating knowledge to practice using The Implementation Roadmap 171 A-3 COVID-19 isolation precautions in immunocompromised oncology patients 171 A-4 Facilitators and barriers in oncology clinical practice influencing nurses’ completion of GRASP 172 A-5 Effectiveness of a standard screening program for intravenous immunoglobulin at community 172 B-1 Enteral versus parenteral nutrition – What is the best for stem cell transplants? 172 B-2 Optimizing oncology nursing scope of practice with added competency of tuberculosis testing 173 B-3 A quality project on improving patient safety: Prostate biopsy 173 B-4 Re-designing the ESAS-r for ambulatory oncology settings 173 C-1 Informal caregivers in palliative care planning: Perception, documentation, and integration 174 C-2 Cancer screening for refugees in OECD countries: A realist review 174 C-3 Addressing hematologic cancer symptom burden through evidence-informed oncology nursing practice 174 C-4 The process of developing a survey that examines the experience of oncology nurses 175 C-5 Support Interventions Offered to Family Members of a Child Treated with HSCT 175 D-1 Patient education development for the “new normal” 175 D-2 The use of simulation-based education in cancer care: A scoping review 176 D-3 Virtual systemic therapy education project 176 D-4 RN reviewers for systemic therapy protocols 176 D-5 JCURA student journey to cancer care nursing 177 D-6 Implementing dementia-friendly care approach for cancer patients living with dementia 177

Abstract:Abstract Clinical cancer research is undergoing a period of fast and unprecedented transformation. Huge progress has been achieved in the deep understanding of multiple malignancies, allowing us to identify the oncogenic molecules and signaling pathways that drive them. The consensus is now to make the emerging knowledge in tumor biology the basis for drug discovery, development and clinical testing, with the aim of targeting specific patient populations that may most likely benefit. Breast cancer, like a number of other malignancies, is a heterogeneous disease with different molecular alterations driving its growth, survival and response to therapy. The current classification of breast cancer subtypes is mainly based on the pattern of expression of hormone receptors (HR) -estrogen receptor and/or progesterone receptor- and the human epidermal growth factor receptor 2 (HER2), which result in three major and distinct molecular breast cancer subtypes: luminal, which is HR positive and HER2 negative; HER2-overexpressed (HER2 positive); and those that lack expression of the three receptors, frequently referred to as triple negative breast cancer (TNBC). While this division is far from perfect and, in addition, subgroups within these groups clearly exist, tumors within these subtypes have similar gene expression patterns, clinical outcomes and responses to therapy. Intertwined with the advances in molecular biology and genomic approaches, which continue increasing our detailed understanding of cancer, has come a torrent of targeted drug candidates. The cancer drug pipeline is nowadays a broad-based pyramid, with lots of molecules in early development that never make it to the top. The new generation of targeted therapies continue to build on their widely used predecessors, trastuzumab and lapatinib, and now include novel anti-HER2 strategies. In addition, targets have diversified to encompass modulators of proliferative signal transduction and cell cycle transit, apoptosis, invasion, angiogenesis and metastasis. Moreover, there are classes of therapies under evaluation that include agents against critically important signaling pathways such as the PI3K/Akt/mTOR inhibitors and inhibitors of DNA repair. The challenges that are being brought by these novel therapies are different from those faced by traditional antitumor strategies. They not only include the identification of appropriate dose and schedule, safety issues, etc., but also the selection of patient populations most likely to benefit. Not less important, central to targeted therapy development is a clear understanding of the molecular biology of signaling pathways and the development of combinatorial strategies, either with chemotherapy, hormonal therapy or other targeted agents. Another layer of complexity is what constitutes a reasonable measure or response and the selection of an attainable and clinically meaningful endpoint. Personalized treatment strategies are without any doubt the way of the future. While the pouring of novel drug candidates is encouraging, challenges arise as to how to better allocate resources and make the development process more efficient. Substantial investments of time and other resources are required for the development of drugs that ultimately fail. But if our drug development process is not working as expected, where is the bottleneck? Traditionally, drug development in oncology has focused mainly on advanced disease. New drugs are usually tested in patients for whom no other approved alternatives are available. Once a drug is proven beneficial -and safe-in this setting, the compound works its way backwards to earlier lines of treatment. Consequently, novel agents are not demonstrated truly beneficial until late in the game, making the drug development process lengthy, expensive, and demanding of patient numbers in the thousands. Also to consider is the fact that advanced tumors usually complex entities, with many accumulated mutations, likely resistant, and with distant foci that do not necessarily share their genetic makeup. It would not be daring to speculate that more than a few clinically active drug candidates have not been pursued due to failure in this setting. The question is, is there a better way? A novel approach to clinical development has been gaining momentum in the breast cancer arena with the advent of neoadjuvant trials. The neoadjuvant setting presents a unique opportunity for the investigation of a molecule's proof-of-concept. Preoperative treatment periods are short, a clinical outcome is objectively measured at the time of surgery, and biomarker analyses can be easily implemented and correlated with clinical results. Additionally, for patients who do not respond optimally, adjuvant treatment with a different regimen can be administered. The use of biomarkers of response in this context could facilitate the efficient evaluation of new agents in focused early clinical trials while enabling the design of more informed, smaller phase II/III trials. In fact, preoperative studies connect clinicians, translational researchers, and radiologists with a new model for the evaluation of treatments in the setting of primary breast cancer: bringing together data from multiple molecular biomarker studies with imaging. In regards to the HER2 positive subtype, trials such as NeoALTTO and NeoSphere have consolidated the notion that dual HER2 blockade is the optimal therapeutic strategy, building upon the NOAH study, which demonstrated the efficacy of trastuzumab and chemotherapy in this setting. Additional findings open the door for possible chemotherapy-free regimens, and the evaluation of early responses by FDG-PET/CT imaging, not to mention the various biomarker analyses being carried out as we speak. Adjuvant trials for both pertuzumab and lapatinib in combination with trastuzumab are currently being conducted with confidence based on the early readout of response. In the case of luminal B breast cancer, a neoadjuvant study including everolimus and letrozole therapy provided the foundation for the design of the BOLERO-2 trial, whose impressive results have been widely celebrated just recently. Finally, in populations that are targetless such as TNBC, the neoadjuvant model is no less important because of the possibility to early evaluate the response and to switch therapies. The neoadjuvant model in breast cancer research is indeed a success. But success is not determined only by the continued development or the regulatory approval of a particular agent or combination; it also represents the early dismissal of drug candidates that do not offer significant clinical activity, in benefit of the allocation of time and resources to other runners. One can only wonder what the story of trastuzumab or lapatinib would have been if they had been developed in this fashion, as opposed to debuting in the metastatic setting. In all likelihood, the adjuvant trials would have been conducted earlier, and perhaps nowadays we would be further ahead in the management of HER2 positive disease. Certainly, a paradigm shift is not without its challenges. Drastic change will always be met with resistance, but the time has come to seriously consider such a brave new world. We owe it to our patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr PL01-04.

First person profile: Betty Ferrell, PhD, RN

First person profile: Robert L. Ferris, MD, PhD

First person profile: Michelle M. Le Beau, PhD

First person profile: Mona Fouad, MD, MPH

First person profile: Patrick J. Loehrer, MD

Welcoming the 20th Volume of Future Oncology

Updates on breast biomarkers

Discrepancy in accelerated approvals for cancer drugs in the United States and Europe

2023 American Society of Hematology meeting roundup

Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches

Abstract A002: Collaboration between the physician/researcher and patient/survivor is key

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

A New Era of Data-Driven Cancer Research and Care: Opportunities and Challenges

Editorial: Reviews in breast cancer: 2023

Proceedings of the 2022 CANO Conference

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Abstract PL01-04: The neoadjuvant model in breast cancer research: Stories of success.

Therapies for the Treatment of Advanced/Metastatic Estrogen Receptor-Positive Breast Cancer: Current Situation and Future Directions

Abstract 3143: Monitoring circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) genomic alterations in ER positive (POS)/HER2 negative (NEG) advanced breast cancer during endocrine therapy: correlative study of AZD9496 oral SERD phase I trial

Abstract A063: CancerTools.org: Research Tools Supporting Breast Cancer Studies